Vilin Bio Med Past Earnings Performance
Past criteria checks 5/6
Vilin Bio Med has been growing earnings at an average annual rate of 58.4%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 35.8% per year. Vilin Bio Med's return on equity is 6.2%, and it has net margins of 9.1%.
Key information
58.4%
Earnings growth rate
51.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 35.8% |
| Return on equity | 6.2% |
| Net Margin | 9.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vilin Bio Med makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 160 | 15 | 8 | 0 |
| 30 Jun 23 | 142 | 14 | 8 | 0 |
| 31 Mar 23 | 123 | 12 | 8 | 0 |
| 31 Mar 22 | 112 | 0 | 9 | 0 |
| 31 Mar 21 | 117 | 1 | 11 | 0 |
| 31 Mar 20 | 168 | 2 | 14 | 0 |
Quality Earnings: VILINBIO has high quality earnings.
Growing Profit Margin: VILINBIO's current net profit margins (9.1%) are higher than last year (5.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VILINBIO's earnings have grown significantly by 58.4% per year over the past 5 years.
Accelerating Growth: VILINBIO's earnings growth over the past year (128.2%) exceeds its 5-year average (58.4% per year).
Earnings vs Industry: VILINBIO earnings growth over the past year (128.2%) exceeded the Pharmaceuticals industry 23.4%.
Return on Equity
High ROE: VILINBIO's Return on Equity (6.2%) is considered low.